This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Tumor microenvironment antigens
Seminars in Immunopathology Open Access 29 September 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S et al. Immunogenicity of Bcl-2 in cancer patients. Blood 2004, (in press).
Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998; 92: 3226–3239.
Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567–1576.
Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S, Wang HG et al. Expression of multiple apoptosis-regulatory genes in human breast cancer cell lines and primary tumors. Breast Cancer Res Treat 1998; 47: 129–140.
Tang L, Tron VA, Reed JC, Mah KJ, Krajewska M, Li G et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4: 1865–1871.
Shangary S, Johnson DE . Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003; 17: 1470–1481.
Zhang B, Gojo I, Fenton RG . Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99: 1885–1893.
Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 1998; 92: 3226–3239.
Andersen MH, Tan L, Sondergaard I, Zeuthen J, Elliott T, Haurum JS . Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 2000; 55: 519–531.
Andersen MH, Pedersen LO, Becker JC, thor Straten P . Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res 2001; 61: 869–872.
Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM et al. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 2002; 20: 98:409–98:414.
Moshynska O, Sankaran K, Pahwa P, Saxena A . Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. J Natl Cancer Inst 2004; 96: 673–682.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Andersen, M., Becker, J. & thor Straten, P. The antiapoptotic member of the Bcl-2 family Mcl-1 is a CTL target in cancer patients. Leukemia 19, 484–485 (2005). https://doi.org/10.1038/sj.leu.2403621
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403621